CD40-activated B cells as antigen-presenting cells: the final sprint toward clinical application

CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells

(2012) Masayasu Naito et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells

(2012) Alexander Shimabukuro-Vornhagen et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Tuning of CD40–CD154 Interactions in Human B-Lymphocyte Activation: A Broad Array of In Vitro Models for a Complex In Vivo Situation

(2011) Sonia Néron et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Activated primary human B cells efficiently induce early CD40L and CD107a expression in CD4+ T cells

(2011) S. Theurich et al.   BLOOD

Adoptive Transfer of Tumor Reactive B Cells Confers Host T-Cell Immunity and Tumor Regression

(2011) Q. Li et al.   CLINICAL CANCER RESEARCH

Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis

(2011) Andreas Draube et al.   PLoS One

CD40-Activated B Cell Cancer Vaccine Improves Second Clinical Remission and Survival in Privately Owned Dogs with Non-Hodgkin's Lymphoma

(2011) Karin U. Sorenmo et al.   PLoS One

Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy

(2011) Chao Wu et al.   Virology Journal

TGFß, a Potent Regulator of Tumor Microenvironment and Host Immune Response, Implication for Therapy

(2010) L. Yang   CURRENT MOLECULAR MEDICINE

Biology of interleukin-10

(2010) Robert Sabat et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Activated human B cells: stimulatory or tolerogenic antigen-presenting cells?

(2009) A. Shimabukuro-Vornhagen et al.   BLOOD

Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen

(2009) S Guo et al.   GENE THERAPY

Using CD40-activated B Cells to Efficiently Identify Epitopes of Tumor Antigens

(2009) Eisei Kondo et al.   JOURNAL OF IMMUNOTHERAPY

Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells

(2008) W. Tu et al.   BLOOD

Induction of CD4+ T-cell anergy and apoptosis by activated human B cells

(2008) T. Tretter et al.   BLOOD

Cyclin D1-Specific Cytotoxic T Lymphocytes Are Present in the Repertoire of Cancer Patients: Implications for Cancer Immunotherapy

(2008) E. Kondo et al.   CLINICAL CANCER RESEARCH

Twelve immunotherapy drugs that could cure cancers

(2008) Martin A. ‘Mac’ Cheever   IMMUNOLOGICAL REVIEWS

CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides

(2008) Tahamtan Ahmadi et al.   IMMUNOLOGY

Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species

(2008) Mathias W. Pletz et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Conditional Immortalization of Human B Cells by CD40 Ligation

(2008) Martina Wiesner et al.   PLoS One